Edison Pharmaceuticals Receives Commendation From the City of San Jose

    SAN JOSE, Calif., July 7 /PRNewswire/ -- Edison Pharmaceuticals, Inc.,
 a privately held biotechnology company located in San Jose, CA, announced
 today the receipt of a commendation from the City of San Jose,
 acknowledging the company's contributions in fighting rare childhood
 diseases. The commendation recognizes "Edison for outstanding achievements
 in developing drugs for unmet medical need, and its commitment to
 public-private partnership, and extend our best wishes for many years of
 success in positively impacting the lives of children and individuals with
 mitochondrial diseases in America and throughout the world."
 
     Mayor Chuck Reed and Councilmember Forrest Williams presented the
 commendation to Edison Chairman and CEO, Dr. Guy Miller on February 12th,
 2008 at City Hall. "Since starting operations at the San Jose BioCenter in
 January 2006, Edison Pharmaceuticals has helped to make San Jose a center
 of life science technology. Edison is doing a remarkable job by focusing
 its R&D efforts on discovering a treatment for mitochondrial diseases --
 that impair energy metabolism, and for which there exist no drugs," said
 Mayor Chuck Reed. "I congratulate Edison on achieving high performance
 standards and for the commitment of its founder Dr. Guy Miller and his team
 to improving the lives of children throughout the world."
 
     About Edison Pharmaceuticals
 
     Edison Pharmaceuticals, Inc., a biotechnology company based in Silicon
 Valley California at the San Jose Biocenter, is focused on developing drugs
 for rare diseases that impair energy metabolism. Edison possesses a
 technology platform and specialized knowledge in redox therapeutics --
 pivotal to targeting genetic defects in the mitochondria. The Company's
 initial focus is on inherited diseases of the mitochondrial respiratory
 chain. The company is leveraging insights derived from those studies to
 pursue other diseases that share common mechanisms, such as Huntington's
 disease and diseases of aging. Edison has obtained substantial
 peer-reviewed grants from multiple foundations and the National Institutes
 of Health.
 
 
 

SOURCE Edison Pharmaceuticals, Inc.